Pluri Inc. Asset Resilience Ratio
Pluri Inc. asset resilience ratio. Pluri Inc. (PLUR) has an Asset Resilience Ratio of 22.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PLUR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pluri Inc. (2007–2025)
Asset resilience ratio of Pluri Inc. from 2007 to 2025. This chart shows how Pluri Inc.'s Asset Resilience Ratio has changed over time. Read PLUR current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pluri Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pluri Inc. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.90 Million | 22.65% |
| Total Liquid Assets | $5.90 Million | 22.65% |
Asset Resilience Insights
- Good Liquidity Position: Pluri Inc. maintains a healthy 22.65% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Pluri Inc. Industry Peers by Asset Resilience Ratio
Compare Pluri Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Pluri Inc. Asset Resilience Ratio by Year (2007–2025)
Pluri Inc. asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Pluri Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 38.05% | $14.72 Million | $38.68 Million | -20.65pp |
| 2024-06-30 | 58.70% | $23.20 Million | $39.53 Million | -9.83pp |
| 2023-06-30 | 68.53% | $34.81 Million | $50.80 Million | +2.06pp |
| 2022-06-30 | 66.47% | $45.24 Million | $68.06 Million | +30.43pp |
| 2021-06-30 | 36.04% | $33.71 Million | $93.54 Million | -21.21pp |
| 2020-06-30 | 57.25% | $37.51 Million | $65.53 Million | -5.35pp |
| 2019-06-30 | 62.60% | $19.60 Million | $31.31 Million | +8.49pp |
| 2018-06-30 | 54.10% | $21.08 Million | $38.96 Million | -2.91pp |
| 2017-06-30 | 57.01% | $21.40 Million | $37.53 Million | +0.45pp |
| 2016-06-30 | 56.56% | $25.98 Million | $45.94 Million | +13.40pp |
| 2015-06-30 | 43.16% | $29.42 Million | $68.16 Million | -23.59pp |
| 2014-06-30 | 66.75% | $49.41 Million | $74.02 Million | +1.04pp |
| 2013-06-30 | 65.71% | $44.89 Million | $68.32 Million | +50.90pp |
| 2012-06-30 | 14.81% | $7.02 Million | $47.42 Million | -10.13pp |
| 2009-06-30 | 24.94% | $1.11 Million | $4.46 Million | -8.13pp |
| 2008-06-30 | 33.06% | $1.19 Million | $3.58 Million | -22.81pp |
| 2007-06-30 | 55.87% | $3.76 Million | $6.73 Million | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, … Read more